Jimeno JM - Search Results

1

Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19.

Varona JF, Landete P, Lopez-Martin JA, Estrada V, Paredes R, Guisado-Vasco P, Fernandez de Orueta L, Torralba M, Fortun J, Vates R, Barberan J, Clotet B, Ancochea J, Carnevali D, Cabello N, Porras L, Gijon P, Monereo A, Abad D, Zuñiga S, Sola I, Rodon J, Vergara-Alert J, Izquierdo-Useros N, Fudio S, Pontes MJ, de Rivas B, Giron de Velasco P, Nieto A, Gomez J, Aviles P, Lubomirov R, Belgrano A, Sopesen B, White KM, Rosales R, Yildiz S, Reuschl AK, Thorne LG, Jolly C, Towers GJ, Zuliani-Alvarez L, Bouhaddou M, Obernier K, McGovern BL, Rodriguez ML, Enjuanes L, Fernandez-Sousa JM, Krogan NJ, Jimeno JM, Garcia-Sastre A. Varona JF, et al. Among authors: jimeno jm. Life Sci Alliance. 2022 Jan 10;5(4):e202101200. doi: 10.26508/lsa.202101200. Print 2022 Apr. Life Sci Alliance. 2022. PMID: 35012962 Free PMC article. Clinical Trial.

2

Plitidepsin for the management of a cancer patient infected with SARS-CoV-2 while receiving chemotherapy.

Guisado-Vasco P, González-Cortijo L, D'Errico G, Serrera-Alvarez A, Sotres-Fernandez G, García-Coca M, Fernández-Sousa JM, Luepke-Estefan XE, López-Martín JA, Jimeno JM. Guisado-Vasco P, et al. Among authors: jimeno jm. Ann Oncol. 2021 Oct;32(10):1295-1297. doi: 10.1016/j.annonc.2021.07.003. Epub 2021 Jul 7. Ann Oncol. 2021. PMID: 34242743 Free PMC article. No abstract available.

3

Plitidepsin as a successful rescue treatment for prolonged viral SARS-CoV-2 replication in a patient with previous anti-CD20 monoclonal antibody-mediated B cell depletion and chronic lymphocytic leukemia.

Guisado-Vasco P, Carralón-González MM, Aguareles-Gorines J, Martí-Ballesteros EM, Sánchez-Manzano MD, Carnevali-Ruiz D, García-Coca M, Barrena-Puertas R, de Viedma RG, Luque-Pinilla JM, Sotres-Fernandez G, Fernández-Sousa JM, Luepke-Estefan XE, López-Martín JA, Jimeno JM. Guisado-Vasco P, et al. Among authors: jimeno jm. J Hematol Oncol. 2022 Jan 10;15(1):4. doi: 10.1186/s13045-021-01220-0. J Hematol Oncol. 2022. PMID: 35012608 Free PMC article.

4

Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.

Izquierdo MA, Bowman A, García M, Jodrell D, Martinez M, Pardo B, Gómez J, López-Martin JA, Jimeno J, Germá JR, Smyth JF. Izquierdo MA, et al. Clin Cancer Res. 2008 May 15;14(10):3105-12. doi: 10.1158/1078-0432.CCR-07-1652. Clin Cancer Res. 2008. PMID: 18483378 Clinical Trial.

5

Progress in the clinical development of new marine-derived anticancer compounds.

Jimeno J, López-Martín JA, Ruiz-Casado A, Izquierdo MA, Scheuer PJ, Rinehart K. Jimeno J, et al. Anticancer Drugs. 2004 Apr;15(4):321-9. doi: 10.1097/00001813-200404000-00003. Anticancer Drugs. 2004. PMID: 15057135 Review.

6

Reports of clinical benefit of plitidepsin (Aplidine), a new marine-derived anticancer agent, in patients with advanced medullary thyroid carcinoma.

Le Tourneau C, Faivre S, Ciruelos E, Domínguez MJ, López-Martín JA, Izquierdo MA, Jimeno J, Raymond E. Le Tourneau C, et al. Am J Clin Oncol. 2010 Apr;33(2):132-6. doi: 10.1097/COC.0b013e318199fb6e. Am J Clin Oncol. 2010. PMID: 19687728 Clinical Trial.

7

Phase I clinical and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer.

Rademaker-Lakhai JM, Horenblas S, Meinhardt W, Stokvis E, de Reijke TM, Jimeno JM, Lopez-Lazaro L, Lopez Martin JA, Beijnen JH, Schellens JH. Rademaker-Lakhai JM, et al. Among authors: jimeno jm. Clin Cancer Res. 2005 Mar 1;11(5):1854-62. doi: 10.1158/1078-0432.CCR-04-1534. Clin Cancer Res. 2005. PMID: 15756010 Clinical Trial.

8

Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors.

Pardo B, Paz-Ares L, Tabernero J, Ciruelos E, García M, Salazar R, López A, Blanco M, Nieto A, Jimeno J, Izquierdo MA, Trigo JM. Pardo B, et al. Among authors: jimeno j. Clin Cancer Res. 2008 Feb 15;14(4):1116-23. doi: 10.1158/1078-0432.CCR-07-4366. Clin Cancer Res. 2008. PMID: 18281545 Clinical Trial.

9

In vitro radiosensitisation by trabectedin in human cancer cell lines.

Romero J, Zapata I, Córdoba S, Jimeno JM, López-Martín JA, Tercero JC, De La Torre A, Vargas JA, Molerón R, Sánchez-Prieto R. Romero J, et al. Among authors: jimeno jm. Eur J Cancer. 2008 Aug;44(12):1726-33. doi: 10.1016/j.ejca.2008.04.013. Epub 2008 May 22. Eur J Cancer. 2008. PMID: 18501589

10

Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies.

Forouzesh B, Hidalgo M, Chu Q, Mita A, Mita M, Schwartz G, Jimeno J, Gómez J, Alfaro V, Lebedinsky C, Zintl P, Rowinsky EK. Forouzesh B, et al. Clin Cancer Res. 2009 May 15;15(10):3591-9. doi: 10.1158/1078-0432.CCR-08-2889. Epub 2009 May 5. Clin Cancer Res. 2009. PMID: 19417019 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

141 results

Search Page